Here we use the results from this study, in combination with previously identified modifiers, to obtain absolute risks of developing breast and ovarian cancer for BRCA1 mutation carriers based on the joint distribution of all known genetic risk modifiers. This evidence concerns the gene BRCA1 and ovarian cancer.